<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003533</url>
  </required_header>
  <id_info>
    <org_study_id>SPK-8011-101</org_study_id>
    <nct_id>NCT03003533</nct_id>
  </id_info>
  <brief_title>A Gene Transfer Study for Hemophilia A</brief_title>
  <official_title>Gene Transfer, Dose-Finding Safety, Tolerability, and Efficacy Study of SPK-8011 [a Recombinant Adeno-Associated Viral Vector With Human Factor VIII Gene] in Individuals With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spark Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spark Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the
      safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals
      with hemophilia A.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemophilia A is a condition in which blood is unable to clot effectively. It is caused by a
      mutation or deletion in the gene that is responsible for producing blood-clotting factor VIII
      protein. Individuals with hemophilia A suffer from repeated bleeding episodes, often into the
      joints, which can cause chronic joint disease and sometime results in death due to the
      inability of the blood to clot efficiently. This chronic joint disease can have significant
      physical, psychosocial, and quality-of-life effects, including financial burden. The current
      treatment is intravenous (i.v.) injections of factor VIII protein products, either 2-3 times
      weekly or in response to bleeding.

      Recent preliminary clinical data of a hemophilia B gene transfer study (which is also being
      conducted by Spark Therapeutics) shows all study participants achieving therapeutic factor IX
      activity levels (average of maintaining factor IX activity levels around 30% of normal with
      no confirmed bleeds, after receiving Spark gene transfer, with the approach of using the
      novel bio-engineered recombinant adeno-associated viral (rAAV) vector carrying a high
      specific activity of a factor IX gene. The approach being tested in this clinical research
      study uses a further modified novel AAV vector (with a stronger attraction to the human
      liver) to deliver the human factor VIII (hFVIII) gene into liver cells so that they can
      produce factor VIII protein.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of study-related adverse events, including clinically significant abnormal laboratory values</measure>
    <time_frame>52 weeks</time_frame>
    <description>adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in FVIII activity levels after a single outpatient administration of SPK-8011</measure>
    <time_frame>52 weeks</time_frame>
    <description>changes in FVIII activity levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetic assessment of SPK-8011 including shedding of vector DNA in bodily fluids</measure>
    <time_frame>52 weeks</time_frame>
    <description>vector shedding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring a course of steroid therapy for the elevations in liver enzymes</measure>
    <time_frame>52 weeks</time_frame>
    <description>number of participants requiring steroids</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>SPK-8011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SPK-8011</intervention_name>
    <description>A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene</description>
    <arm_group_label>SPK-8011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males age18 years or older

          -  Confirmed diagnosis of hemophilia A as evidenced by their medical history with plasma
             FVIII activity levels ≤ 2% of normal

          -  Have received &gt;150 exposure days (EDs) to FVIII concentrates or cryoprecipitate

          -  Have experienced &gt;10 bleeding events over the previous 12 months only if receiving
             on-demand therapy and having FVIII baseline level 1-2% of normal

          -  Have no prior history of allergic reaction to any FVIII product

          -  Have no measurable inhibitor against factor VIII inhibitor as assessed by the central
             laboratory and have no prior history of inhibitors to FVIII protein

          -  Agree to use reliable barrier contraception

        Exclusion Criteria:

          -  Evidence of active hepatitis B or C

          -  Currently on antiviral therapy for hepatitis B or C

          -  Have significant underlying liver disease

          -  Have serological evidence* of HIV-1 or HIV-2 with CD4 counts ≤200/mm3 (* participants
             who are HIV+ and stable with CD4 count &gt;200/mm3 and undetectable viral load are
             eligible to enroll)

          -  Have detectable antibodies reactive with AAV-Spark200 capsid

          -  Participated in a gene transfer trial within the last 52 weeks or in a clinical trial
             with an investigational product within the last 12 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director</last_name>
    <role>Study Director</role>
    <affiliation>Spark Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Director</last_name>
    <email>clinicaltrials@sparktx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Davis - Hemostasis and Thrombosis Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>94817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Giermasz, M.D., Ph.D.</last_name>
      <phone>916-734-1293</phone>
      <email>giermasz@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erika Adams</last_name>
      <phone>(916) 734-7633</phone>
      <email>ejadams@ucdavis.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Croteau, MD</last_name>
      <email>Stacy.Croteau@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Felicia Ciuculescu</last_name>
      <phone>617-632-1955</phone>
      <email>Felicia.Ciuculescu@childrens.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mississippi Center for Advanced Medicine</name>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spencer K. Sullivan, M.D.</last_name>
      <phone>601-499-0935</phone>
      <email>SKSullivan@msadvancedmedicine.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine-Comprehensive Center for Hemophilia and Coagulation Disorders</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine McGuinn, M.D.</last_name>
      <phone>212-746-3978</phone>
      <email>cam9061@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ilene Goldberg, R.N.</last_name>
      <email>igoldber@med.cornell.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pennslyvania State University Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>10733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Eyster, MD</last_name>
      <email>meyster@hmc.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gail Long</last_name>
      <phone>717-531-6603</phone>
      <email>glong@hmc.psu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey George, M.D.</last_name>
      <email>GeorgeL@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ben Samelson-Jones, M.D., Ph.D.</last_name>
      <email>SamelsonJonesB@email.chop.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hemophilia Center of Western Pennsylvania</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Kadosh, R.N., B.S.N.</last_name>
      <phone>412-209-7263</phone>
      <email>JKadosh@itxm.org</email>
    </contact>
    <contact_backup>
      <last_name>Margaret V Ragni, M.D.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University School of Medicine</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Christian Barrett, MD</last_name>
      <phone>804-827-3306</phone>
      <email>jcbarrett@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janice Kuhn</last_name>
      <phone>804-827-3306</phone>
      <email>janice.kuhn@vcuhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hosptial</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Rasko, MD</last_name>
      <phone>+029 5656156</phone>
      <email>j.rasko@centenary.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jerry Teitel, MD</last_name>
      <phone>416-864-5245</phone>
      <email>teitelj@smh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Pertucci</last_name>
      <phone>416-864-6060</phone>
      <email>pertuccij@smh.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adeno-Associated Virus (AAV)</keyword>
  <keyword>Blood Coagulation Disorders</keyword>
  <keyword>Blood Coagulation Disorders, Inherited</keyword>
  <keyword>Coagulation Protein Disorders</keyword>
  <keyword>Factor VIII (FVIII)</keyword>
  <keyword>Factor VIII (FVIII) Deficiency</keyword>
  <keyword>Factor VIII (FVIII) Gene</keyword>
  <keyword>Factor VIII (FVIII) Protein</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Genetic Diseases, X-Linked</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Gene Transfer</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Recombinant</keyword>
  <keyword>Vector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

